GlassScriptPhysician profile
Kendall Harris
NPI 1275582009
$5,334.57
in general payments reported to CMS, 2019-2025
21 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,159 · 2020: $469 · 2021: $1,307 · 2022: $930 · 2023: $541 · 2024: $512 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,542.49 | 2019-2025 | Total30, Precision 1, Precision7 |
| Johnson & Johnson Vision Care, INC. | $979.27 | 2019-2024 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $671.67 | 2019-2021 | |
| Biotissue Holdings INC. | $279.82 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $264.89 | 2022-2024 | Miebo, Xiidra, Infuse |
| Coopervision INC. | $245.16 | 2019-2024 | Biofinity Contact Lens, Misight Contact Lens, Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $229.37 | 2021-2022 | |
| Carl Zeiss Meditec, INC. | $196.26 | 2019 | |
| Mallinckrodt Hospital Products INC. | $177.96 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $133.21 | 2021 | |
| Eyevance Pharmaceuticals LLC | $122.73 | 2020-2021 | |
| Abbvie INC. | $118.03 | 2021-2022 | |
| Allergan, INC. | $80.46 | 2021-2022 | |
| Oyster Point Pharma, INC. | $76.16 | 2022-2024 | Ryzumvi, Tyrvaya |
| Regeneron Pharmaceuticals, INC. | $59.05 | 2025 | Eylea Hd |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $37.89 | 2023 | |
| Maculogix, INC. | $35.45 | 2021 | |
| Integra Lifesciences Corporation | $26.30 | 2024 | Biodoptix, Biodfactor, Biofix |
| Alexion Pharmaceuticals, INC. | $23.78 | 2023 | |
| Harrow Eye, LLC | $22.36 | 2024 | Vevye |
| Novartis Pharmaceuticals Corporation | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.